From DCAT Value Chain Insights (VCI)
AMRI has appointed Louis Yu, PhD, to the newly created position of senior vice president of quality and compliance. Dr. Yu will report to William S. Marth, AMRI's president and CEO. Dr. Yu will oversee all aspects of quality and cGMP compliance at all divisions of AMRI, including Drug Discovery Services, API and Drug Product Development and Manufacturing.
Dr. Yu comes to AMRI with over 30 years of leadership experience in the quality and R&D functions of branded and generic pharmaceutical companies. Most recently, he served as executive vice president, global quality & compliance for Perrigo, a manufacturer of private label and branded over-the-counter and generic prescription pharmaceutical products. There, he was responsible for strategic leadership and management of the global quality function. He led traditional quality and regulatory compliance as well as the global patient safety/medical affairs department. Prior to that, he served as vice president of quality for CV Therapeutics, now a division of Gilead. Earlier in his career, he served as the most senior quality leader at Forest Laboratories, Solvay Pharmaceuticals and Par Pharmaceutical as well as with increasing level of responsibilities in the quality and R&D organizations of the J&J Companies.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription